Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

The New England journal of medicine - 6 May 2010

Zimmerhackl Lothar Bernd, Hofer Johannes, Cortina Gérard, Mark Walter, Würzner Reinhard, Jungraithmayr Therese C, Khursigara Gus, Kliche Kay O, Radauer Wolfgang

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Complement Activation
Share to Complement C3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement Factor H

Share to Graft Survival

Share to Hemolytic-Uremic Syndrome

Share to Kidney Transplantation

Share to Secondary Prevention

Source

Identifiers

PMID: 20445192
DOI: 10.1056/NEJMc1001060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.PMID 20445192Read ↗

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.Semantic proximity Read ↗

Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.Semantic proximity Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read ↗

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.Semantic proximity Read ↗

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read ↗

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.Semantic proximity Read ↗

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.